The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes

Pharmacy World and Science

Volumn 29, Issue 5, 2007, Pages 541-545

  Lowey, Andrew ^a,b   Moore, Sara ^b   Norris, Catherine ^a   Wright, David ^c   Silcock, Jonathan ^d   Hammond, Peter ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b HARROGATE AND DISTRICT NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cardiovascular risk; Cost effectiveness; Diabetes mellitus; Hyperlipidaemia; Hypertension; Pharmacist; Pharmacoeconomics; Pharmacy; United Kingdom

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

AGED; ALGORITHM; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED PRACTICE; FEMALE; GENERAL HOSPITAL; HEALTH CARE COST; HOSPITAL DISCHARGE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT INFORMATION; PATIENT REFERRAL; PHARMACIST; PUBLIC HOSPITAL; RISK REDUCTION; RURAL AREA; UNITED KINGDOM;

AGED; ALGORITHMS; AMBULATORY CARE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ENGLAND; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; PHARMACISTS; RISK FACTORS; STROKE;

EID: 34548561514     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9101-7     Document Type: Article

References (20)

1. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419
2. Stratton IM, Adler AT, Neil HAW, Matthews DR, Manley SE, Cull CA et al. Epidemiological associations of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000;321:405-412
3. Diabetes NSF Team. National service framework for diabetes: standards. London:Department of Health;2001
4. Yki-Jarvinen H. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs 2000;60:975-983
5. UKPDS Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clin Sci 2001; 101:671-679
6. National Institute for Clinical Excellence (2002). Management of type 2 diabetes: management of blood pressure and blood lipids (Guideline H). London: NICE;2002 (ISBN 1-84257-251-2)
7. Audit Commission. A spoonful of sugar - medicines management in NHS hospitals. London: Audit Commission Publications;2001 (ISBN 1-86240-321-X)
8. Crown J. Review of prescribing, supply and administration of medicines. London:NHS Executive; 1998
9. Secretary of State for Health. Health & Social Care Act 2001. London: Stationary Office;2001 [Chapter 15].
10. National Health Service (Pharmaceutical Services) (General Medical Services) and (Charges for Drugs and Appliances). Amendment Regulations 2003. London: The Stationary Office;2003 [Statutory Instruments 2003 No. 1084]
11. Ramsay LE, Williams B, Johnson GD, MacGregor GA, Poston L, Potter JF et al. Guidelines for the management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-592
12. Pyorala K, Pedersen TR, Kjekshus J, Faergerman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997;20:614-620
13. Goldberg R, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-2519
14. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
15. Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML et al. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. Clin Ther 2003;25:119-138
16. British National Formulary No 43 (March 2002) (Published by British Medical Association & Royal Pharmaceutical Society of Great Britain) ISBN 0521770297
17. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. NEJM 2003; 348:383-393
18. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998;317:703-713
19. The HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study. Lancet 2000;355:253-259
20. Secretary of State for Health. The NHS plan: a plan for investment, a plan for reform. London; Department of Health; 2000 (Cm 4818-I)